FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo

AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory limbo.